J & J Va terminando la Fase II del Yondelis en Treatment of Localized Myxoid / Round Liposarcoma . not recruiting participants .

The purpose of this study is to determine the effects that trabectedin has on Myxoid / round cell liposarcoma (MRCL) when it is given before the tumor is removed by surgery.

Further study details as provided by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.:
Primary Outcome Measures:
To determine the pathological complete response (pCR) rate with trabectedin in patients with localized myxoid / round cell liposarcoma (MRCL)
Secondary Outcome Measures:
Evaluate objective response rate by RECIST & contrast such responses with changes in radiological density & tumor pathology. Describe the incidence & severity of adverse events in this patient population; hypothesis-generating pharmacogenomic analyses

Estimated Enrollment: 22
Study Start Date: May 2007
Last Updated: January 29, 2009

Más del 25% de los españoles tendrá cáncer . 4 Febrero , Dia Mundial del Cáncer .

El cáncer sigue siendo la plaga del Siglo XXI según la Sociedad Española de Oncología Médica (SEOM) que señaló ayer que el 25 por ciento de la población de nuestro país padecerá cáncer a lo largo de su vida ...